President Trump is continuing his push to bring pharmaceutical production back to the United States, this time by turning to tariffs on medications made abroad. According to the plan, he is preparing steep tariff rates on certain drugs that are manufactured overseas, framing the move as part of a broader effort to reshape where the country's medicines are produced.
The details of the plan were laid out in a social media post from Trump yesterday. Rather than an immediate across-the-board tax, the post described a phased approach specifically targeting generic drugs, the lower-cost medications that make up a large share of what patients in the United States take every day.
Under the outlined timeline, there would be a grace period at the start. As of this August, generic drugs brought into the U.S. will continue to have a 0% tariff for two years. That window is intended to give the market time before the higher rates take effect, according to the plan described in the post.
After that initial period, however, the rates would climb sharply. The post said tariff rates on generic drugs will spike to 100% in 2028, and then rise again to 200% in 2029. Such a steep escalation would represent a dramatic increase in the cost of importing these medications into the country.
The potential impact is significant because of how central generic drugs are to the U.S. market. The FDA says 90% of the medications sold in the United States are generic drugs, meaning the vast majority of prescriptions filled across the country fall into the category that the planned tariffs would target.
Where those generic drugs come from is also a key part of the picture. According to the FDA, generic medications are most commonly manufactured in India. That makes the planned tariffs particularly relevant for the supply chain that currently delivers a large portion of the drugs Americans rely on.